Clinical pattern recognition. Commercial execution. Peer-reviewed methodology.
SHAARPEC was built by people who already knew how to do the hard parts — a Harvard Medical School emergency physician who reads patient trajectories in real time, entrepreneurs with multi-billion dollar exit track records in digital health, and a research team whose predictive algorithms have been published in BMJ Open, JMIR, NPJ Digital Medicine, and European Psychiatry.
LEADERSHIP
The people building SHAARPEC
Chief Executive Officer
Multi-exit digital health entrepreneur and Entrepreneur in Residence at the Mass General Brigham digital innovation team — one of the most active health system innovation programs in the US. Tom brings the commercial and strategic instincts of a founder who has built, scaled, and exited companies in this space, combined with an inside view of how large academic health systems evaluate and adopt new technology. He leads company strategy, business development, and investor relations.
Chief Medical Officer
Emergency medicine physician and Assistant Professor at Harvard Medical School, with a clinical appointment at Brigham and Women’s Hospital. Emergency medicine is the discipline most dependent on reading patient trajectory in real time — integrating sequences of clinical events to anticipate where a patient is heading, before the picture is complete. That clinical instinct is the foundation of SHAARPEC Foresight’s predictive architecture. Philip leads scientific strategy, client engagement, and the design of the platform’s trajectory-based analytics.
Thomas Davidsson
Chief Operating Officer
Swedish digital health entrepreneur with an MBA from the Stockholm School of Economics and a track record of building and scaling health technology companies — with exits representing billions of dollars in growth. Thomas co-founded SHAARPEC and built its European foundation, leading commercial engagements with AstraZeneca, Takeda, Bristol Myers Squibb, Novartis, and Novo Nordisk. He oversees operations, international expansion, and the company’s strategic partnerships across the EU and US markets. Thomas is also a co-author on published research applying transformer-based machine learning to clinical EHR data, including a 2026 study on early ADHD detection published in European Psychiatry.
Chief Business Officer
Healthcare finance, strategy, and M&A leader with deep private equity experience in healthcare and life sciences. Sal understands how large organizations evaluate, finance, and commit to new technology — a perspective that shapes how SHAARPEC approaches both commercial partnerships and investor relationships. He drives the company’s commercial growth strategy, investor engagement, and financial operations.
Farzaneh Etminani, PhD
Lead Data Scientist
PhD researcher and faculty member at Halmstad University and Region Halland, with expertise in AI, machine learning, and predictive modeling applied to longitudinal healthcare data. Farzaneh is the intellectual architect of SHAARPEC Foresight’s trajectory modeling methodology, and her published research is the scientific foundation SHAARPEC Foresight is built on. She is a co-author on the CONSIDERING-AF study (BMJ Open, 2024) — which demonstrated a 5.4× improvement in atrial fibrillation detection across 330,000 patients — the HaRP heart failure readmission study (European Heart Journal / JMIR, 2023), and a 2026 study on early ADHD detection using transformer-based machine learning published in European Psychiatry. Her work spans cardiovascular disease, psychiatry, and foundational EHR trajectory modeling methodology.